These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Examining the cost per caregiver of an intervention designed to improve the quality of life of spousal caregivers of stroke survivors. Parker EK; Swint JM; Godwin KM; Ostwald SK Rehabil Nurs; 2012; 37(5):244-51. PubMed ID: 22949277 [TBL] [Abstract][Full Text] [Related]
7. Accounting for the missing opportunity costs in incremental cost-outcome analysis. Oliver A Appl Health Econ Health Policy; 2002; 1(4):191-6. PubMed ID: 14619248 [TBL] [Abstract][Full Text] [Related]
8. Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine: A Reference, Not a Rule Book. Carias C; Chesson HW; Grosse SD; Li R; Meltzer MI; Miller GF; Murphy LB; Nurmagambetov TA; Pike JJ; Whitham HK Am J Prev Med; 2018 Apr; 54(4):600-602. PubMed ID: 29338958 [No Abstract] [Full Text] [Related]
9. A prospective study on coping strategies and quality of life in patients after stroke, assessing prognostic relationships and estimates of cost-effectiveness. Darlington AS; Dippel DW; Ribbers GM; van Balen R; Passchier J; Busschbach JJ J Rehabil Med; 2009 Mar; 41(4):237-41. PubMed ID: 19247542 [TBL] [Abstract][Full Text] [Related]
10. Unintended consequences of applying economic evaluation. Oliver A J Health Serv Res Policy; 2002 Jul; 7(3):129-30. PubMed ID: 12171741 [No Abstract] [Full Text] [Related]
11. Cost, effectiveness, and cost-effectiveness. Diamond GA; Kaul S Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):49-54. PubMed ID: 20031812 [No Abstract] [Full Text] [Related]
12. Analytic approaches for the evaluation of costs. Glick HA; Polsky D Hepatology; 1999 Jun; 29(6 Suppl):18S-22S. PubMed ID: 10386078 [TBL] [Abstract][Full Text] [Related]
13. Accounting for future costs in medical cost-effectiveness analysis. Meltzer D J Health Econ; 1997 Feb; 16(1):33-64. PubMed ID: 10167344 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of antenatal anti-D prophylaxis. Vick S; Cairns J; Urbaniak S; Whitfield C; Raafat A Health Econ; 1996; 5(4):319-28. PubMed ID: 8880168 [TBL] [Abstract][Full Text] [Related]
15. The limits of cost-effectiveness analysis. Weintraub WS; Cohen DJ Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):55-8. PubMed ID: 20031813 [No Abstract] [Full Text] [Related]
16. Economic considerations for the hepatologist. Provenzale D Hepatology; 1999 Jun; 29(6 Suppl):13S-17S. PubMed ID: 10386077 [TBL] [Abstract][Full Text] [Related]
17. Economic foundations of cost-effectiveness analysis. Garber AM; Phelps CE J Health Econ; 1997 Feb; 16(1):1-31. PubMed ID: 10167341 [TBL] [Abstract][Full Text] [Related]
18. How much are health-care systems prepared to pay to produce a QALY? Buxton MJ Eur J Health Econ; 2005 Dec; 6(4):285-7. PubMed ID: 16258748 [No Abstract] [Full Text] [Related]
19. Economic and Societal Aspects of Stroke Management. Mukundan G; Seidenwurm DJ Neuroimaging Clin N Am; 2018 Nov; 28(4):683-689. PubMed ID: 30322602 [TBL] [Abstract][Full Text] [Related]